CTLA4 and cancer: Cancer immunotherapy with anti-CTLA-4 antibodies modulates the balance of the microbiota–intestinal barrier by inducing IEC-mediated intestinal epithelial cell (IEL) apoptosis, resulting in disruption of the barrier.